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Abstract 
Acneiform rash is the most common side effect of epidermal growth factor receptor (EGFR) 
inhibitors (EGFRis), and it occurs in 50-100% of patients. This condition can affect the quality of 
life of these patients and can sometimes lead to a discontinuation of the antineoplastic therapy. 
Several recent prospective studies have addressed and evaluated different interventions to mitigate 
or reduce the severity of EGFRis-associated skin rash. With this aim, we have established a 
dermocosmetological outpatient clinic for cancer patients at the Department of Clinical Medicine 
and Surgery, University of Naples Federico II in collaboration with the Department of Dermatology 
and Cutaneous Surgery, Miller School of Medicine, University of Miami. An interdisciplinary 
network of physicians can improve the quality of life of the cancer patients, focusing on such 
important aspects as dermocosmetological skin care, but also on the evaluation of new therapeutic 
and diagnostic algorithms in order to make further progress in the field of prevention. In this 
review, we summarize the state of the art of the epidemiology, pathogenesis, and treatment of 
EGFRis acneiform rash, and we describe our outpatient clinical experience.  
 
